RT Journal Article
T1 Design, development, and characterization of an idebenone-loaded poly-ε-caprolactone intravitreal implant as a new therapeutic approach for LHON treatment
A1 Varela Fernández, Rubén
A1 Lema Gesto, María Isabel
A1 González Barcia, Miguel
A1 Otero Espinar, Francisco Javier
K1 Idebenone
K1 Poly-ε-caprolactone
K1 Polymeric implant
K1 LHON
K1 Intravitreal administration
K1 Controlled drug delivery
AB Leber's Hereditary Optic Neuropathy (LHON) is a hereditary mitochondrial neurodegenerative disease of unclear etiology and lack of available therapeutic alternatives. The main goal of the current pilot study was based on the evaluation of the feasibility and characteristics of prolonged and controlled idebenone release from a PCL intravitreal implant. The design, development, and characterization of idebenone-loaded PCL implants prepared by an homogenization/extrusion/solvent evaporation method allowed the obtention of high PY, EE and LC values. In vitro characterization was completed by the assessment of mechanical and instrumental properties. The in vitro release of idebenone from the PCL implants was assessed and the implant erosion was monitored by the mass loss and surface morphology changes. DSC was used to estimate stability and interaction among implant’s components. The present work demonstrated the controlled and prolonged idebenone delivery from the PCL implants in an in vitro model. A consistent preclinical base was established, supporting the idea of idebenone-loaded PCL implants as a new strategy of long-term sustained intraocular delivery for the LHON treatment
PB Elsevier
YR 2021
FD 2021
LK http://hdl.handle.net/10347/27672
UL http://hdl.handle.net/10347/27672
LA eng
NO European Journal of Pharmaceutics and Biopharmaceutics 168 (2021) 195-207. https://doi.org/10.1016/j.ejpb.2021.09.001
NO RVF acknowledges the financial support of the FIDIS (Health Research Institute of Santiago de Compostela Foundation). This work was supported by the Spanish Ministry of Science, Innovation and Universities (RTI2018-099597-B-100)
DS Minerva
RD 24 abr 2026